383 related articles for article (PubMed ID: 24729041)
21. Mammalian target of rapamycin inhibitors for intractable epilepsy and subependymal giant cell astrocytomas in tuberous sclerosis complex.
Cardamone M; Flanagan D; Mowat D; Kennedy SE; Chopra M; Lawson JA
J Pediatr; 2014 May; 164(5):1195-200. PubMed ID: 24518170
[TBL] [Abstract][Full Text] [Related]
22. [Response to everolimus in patients with giant cell astrocytoma associated to tuberous sclerosis complex].
Mateos-González ME; López-Laso E; Vicente-Rueda J; Camino-León R; Fernández-Ramos JA; Baena-Gómez MA; Peña-Rosa MJ
Rev Neurol; 2014 Dec; 59(11):497-502. PubMed ID: 25418144
[TBL] [Abstract][Full Text] [Related]
23. EFFECTS: an expanded access program of everolimus for patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Fogarasi A; De Waele L; Bartalini G; Jozwiak S; Laforgia N; Verhelst H; Petrak B; Pedespan JM; Witt O; Castellana R; Crippa S; Gislimberti G; Gyorsok Z
BMC Neurol; 2016 Aug; 16():126. PubMed ID: 27502586
[TBL] [Abstract][Full Text] [Related]
24. Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis.
Bissler JJ; Nonomura N; Budde K; Zonnenberg BA; Fischereder M; Voi M; Louveau AL; Herbst F; Bebin EM; Curatolo P; Zonta A; Belousova E
PLoS One; 2018; 13(9):e0201005. PubMed ID: 30192751
[TBL] [Abstract][Full Text] [Related]
25. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis.
Krueger DA; Care MM; Holland K; Agricola K; Tudor C; Mangeshkar P; Wilson KA; Byars A; Sahmoud T; Franz DN
N Engl J Med; 2010 Nov; 363(19):1801-11. PubMed ID: 21047224
[TBL] [Abstract][Full Text] [Related]
26. Successful everolimus therapy for SEGA in pediatric patients with tuberous sclerosis complex.
Cappellano AM; Senerchia AA; Adolfo F; Paiva PM; Pinho R; Covic A; Cavalheiro S; Saba N
Childs Nerv Syst; 2013 Dec; 29(12):2301-5. PubMed ID: 23743818
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Renal Angiomyolipoma and Other Hamartomas in Patients with Tuberous Sclerosis Complex.
Samuels JA
Clin J Am Soc Nephrol; 2017 Jul; 12(7):1196-1202. PubMed ID: 28302901
[TBL] [Abstract][Full Text] [Related]
28. Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.
Kotulska K; Chmielewski D; Borkowska J; Jurkiewicz E; Kuczyński D; Kmieć T; Łojszczyk B; Dunin-Wąsowicz D; Jóźwiak S
Eur J Paediatr Neurol; 2013 Sep; 17(5):479-85. PubMed ID: 23567018
[TBL] [Abstract][Full Text] [Related]
29. The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.
Curatolo P; Bjørnvold M; Dill PE; Ferreira JC; Feucht M; Hertzberg C; Jansen A; Jóźwiak S; Kingswood JC; Kotulska K; Macaya A; Moavero R; Nabbout R; Zonnenberg BA
Drugs; 2016 Apr; 76(5):551-65. PubMed ID: 26927950
[TBL] [Abstract][Full Text] [Related]
30. Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis.
Trelinska J; Dachowska I; Kotulska K; Baranska D; Fendler W; Jozwiak S; Mlynarski W
Pediatr Blood Cancer; 2015 Apr; 62(4):616-21. PubMed ID: 25557360
[TBL] [Abstract][Full Text] [Related]
31. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.
Krueger DA; Care MM; Agricola K; Tudor C; Mays M; Franz DN
Neurology; 2013 Feb; 80(6):574-80. PubMed ID: 23325902
[TBL] [Abstract][Full Text] [Related]
32. Adverse Events of Everolimus in Patients with Tuberous Sclerosis Complex Treated for Renal Angiomyolipoma/Subependymal Giant Cell Astrocytoma.
Gau SY; Chen SL; Chang CS; Tsao TF; Tsai JD
Int J Med Sci; 2023; 20(10):1358-1362. PubMed ID: 37786437
[No Abstract] [Full Text] [Related]
33. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study.
French JA; Lawson JA; Yapici Z; Ikeda H; Polster T; Nabbout R; Curatolo P; de Vries PJ; Dlugos DJ; Berkowitz N; Voi M; Peyrard S; Pelov D; Franz DN
Lancet; 2016 Oct; 388(10056):2153-2163. PubMed ID: 27613521
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of everolimus treatment for renal angiomyolipoma associated with tuberous sclerosis complex: A single institution experience in Japan.
Hatano T; Chikaraishi K; Inaba H; Endo K; Egawa S
Int J Urol; 2016 Oct; 23(10):833-838. PubMed ID: 27480662
[TBL] [Abstract][Full Text] [Related]
35. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
36. Everolimus for subependymal giant cell astrocytoma: 5-year final analysis.
Franz DN; Agricola K; Mays M; Tudor C; Care MM; Holland-Bouley K; Berkowitz N; Miao S; Peyrard S; Krueger DA
Ann Neurol; 2015 Dec; 78(6):929-38. PubMed ID: 26381530
[TBL] [Abstract][Full Text] [Related]
37. Everolimus tablets for patients with subependymal giant cell astrocytoma.
Turner SG; Peters KB; Vredenburgh JJ; Desjardins A; Friedman HS; Reardon DA
Expert Opin Pharmacother; 2011 Oct; 12(14):2265-9. PubMed ID: 21806479
[TBL] [Abstract][Full Text] [Related]
38. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA).
Weidman DR; Pole JD; Bouffet E; Taylor MD; Bartels U
Pediatr Blood Cancer; 2015 Oct; 62(10):1754-60. PubMed ID: 25929843
[TBL] [Abstract][Full Text] [Related]
39. Safety of Everolimus in Patients Younger than 3 Years of Age: Results from EXIST-1, a Randomized, Controlled Clinical Trial.
Jóźwiak S; Kotulska K; Berkowitz N; Brechenmacher T; Franz DN
J Pediatr; 2016 May; 172():151-155.e1. PubMed ID: 26858193
[TBL] [Abstract][Full Text] [Related]
40. Effect of everolimus treatment for regrown renal angiomyolipoma associated with tuberous sclerosis complex after transcatheter arterial embolization.
Hatano T; Matsu-Ura T; Mori KI; Inaba H; Endo K; Tamari M; Egawa S
Int J Clin Oncol; 2018 Dec; 23(6):1134-1139. PubMed ID: 30069798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
